Lisata Therapeutics Inc (LSTA)

Feb 06, 2025

Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference - GlobeNewswire

Feb 06, 2025

Feb 05, 2025

Lisata Therapeutics CEO to present at 2025 BIO CEO & Investor Conference - Proactive Investors USA

Feb 05, 2025

Feb 05, 2025

Lisata's Cancer Treatment Pipeline Takes Center Stage at Major Biotech Investor Conference - StockTitan

Feb 05, 2025

Jan 29, 2025

Lisata completes subject enrolment in multi-cancer trial of certepetide - MSN

Jan 29, 2025

Jan 26, 2025

Lisata falls after mid-stage data for anticancer agent - MSN

Jan 26, 2025

Jan 25, 2025

Lisata Therapeutics CEO discusses recent pancreatic cancer trial milestones – ICYMI - Proactive Investors UK

Jan 25, 2025

Jan 24, 2025

Lisata reports positive early trial results for pancreatic cancer drug By Investing.com - Investing.com Australia

Jan 24, 2025

Jan 23, 2025

Lisata Therapeutics Reports Positive Phase 2 Trial Results - TipRanks

Jan 23, 2025

Jan 23, 2025

Lisata Therapeutics CEO David Mazzo on ASCEND and iLSTA Trial Results - Proactive Investors USA

Jan 23, 2025

Jan 23, 2025

Lisata Therapeutics CEO David Mazzo on ASCEND and iLSTA trial results - Proactive Investors USA

Jan 23, 2025

Jan 23, 2025

Lisata Therapeutics and WARPNINE Announce Encouraging - GlobeNewswire

Jan 23, 2025

Jan 23, 2025

Lisata Therapeutics and WARPNINE unveil positive preliminary results from pancreatic cancer trial - Proactive Investors USA

Jan 23, 2025

Jan 23, 2025

Lisata reports positive early trial results for pancreatic cancer drug - Investing.com India

Jan 23, 2025

Jan 23, 2025

Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a - The Bakersfield Californian

Jan 23, 2025

Jan 23, 2025

Lisata's Certepetide Shows Promising Results in Pancreatic Cancer Trial, 63% Response Rate - StockTitan

Jan 23, 2025

Jan 22, 2025

Lisata Therapeutics Shares Tumble After Pancreatic Cancer Treatment Results - MarketWatch

Jan 22, 2025

Jan 22, 2025

Stock market news: Star Fashion Culture Holdings -78.42%, Lisata Therapeutics -33.08% among biggest losers in early trading - Business Upturn

Jan 22, 2025

Jan 22, 2025

Stock market today: Star Fashion Culture Holdings -79.05%, Lisata Therapeutics -23.34% among biggest losers in early trading - Business Upturn

Jan 22, 2025

Jan 22, 2025

Lisata Therapeutics unveils encouraging preliminary data from Phase 2 pancreatic cancer trial - Proactive financial news

Jan 22, 2025

Jan 22, 2025

Lisata stock falls after cancer drug data (LSTA:NASDAQ) - Seeking Alpha

Jan 22, 2025

Jan 22, 2025

Lisata Therapeutics Reports Encouraging Preliminary Cohort - GlobeNewswire

Jan 22, 2025

Jan 22, 2025

Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 - The Bakersfield Californian

Jan 22, 2025

Jan 22, 2025

Lisata's Certepetide Shows 31% Better Survival in Pancreatic Cancer Trial Data - StockTitan

Jan 22, 2025

Jan 21, 2025

First Berlin sets Lisata stock Buy rating on innovative therapies By Investing.com - Investing.com Australia

Jan 21, 2025

Jan 21, 2025

First Berlin sets Lisata stock Buy rating on innovative therapies - MSN

Jan 21, 2025

Jan 15, 2025

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit - GlobeNewswire

Jan 15, 2025

Jan 15, 2025

Lisata Therapeutics CEO to Present at 2025 Sequire Investor Summit in Puerto Rico - StockTitan

Jan 15, 2025

Jan 09, 2025

US Penny Stocks To Watch In January 2025 - Yahoo Finance

Jan 09, 2025

Jan 06, 2025

Beat the Market the Zacks Way: SoFi Technologies, Lisata Therapeutics, AutoZone in Focus - MSN

Jan 06, 2025

Jan 02, 2025

Lisata Therapeutics (NASDAQ:LSTA) Trading Up 1.4% – Still a Buy? - Defense World

Jan 02, 2025

Dec 24, 2024

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation - Simply Wall St

Dec 24, 2024

Dec 23, 2024

2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive Investors UK

Dec 23, 2024

Dec 23, 2024

2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases | NASDAQ:CADL - Proactive Investors UK

Dec 23, 2024

Dec 11, 2024

Lisata Therapeutics advances certepetide with trial enrollment milestone and new diagnostic partnership - Proactive Investors USA

Dec 11, 2024

Dec 11, 2024

Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial - Yahoo Finance

Dec 11, 2024

Dec 11, 2024

Lisata Therapeutics, Inc. Announces Completion of Patient Enrollment in All Three Cohorts of the Phase 1b/2a Cendifox Trial - Marketscreener.com

Dec 11, 2024

Dec 10, 2024

Lisata Therapeutics completes patient enrollment for CENDIFOX trial - Proactive Investors Australia

Dec 10, 2024

Dec 10, 2024

Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial - GlobeNewswire

Dec 10, 2024

Dec 10, 2024

Lisata Therapeutics Hits Major Milestone in Cancer Trial: Full Enrollment Complete for CENDIFOX Study - StockTitan

Dec 10, 2024

Dec 10, 2024

Lisata Therapeutics completes patient enrollment for solid tumor cancer trial - Proactive Investors USA

Dec 10, 2024

Dec 10, 2024

Neostem stock hits 52-week low at $2.41 amid market fluctuations - Investing.com Canada

Dec 10, 2024

Dec 10, 2024

Neostem stock hits 52-week low at $2.41 amid market fluctuations By Investing.com - Investing.com South Africa

Dec 10, 2024

Dec 07, 2024

Lisata Therapeutics and Kuva Labs announce global license agreement for solid tumor imaging - MSN

Dec 07, 2024

Dec 04, 2024

Lisata and Kuva Labs partner for MR imaging agents to detect cancer - Yahoo Finance

Dec 04, 2024

Dec 03, 2024

Lisata Therapeutics inks major deal with Kuva Labs - Investing.com

Dec 03, 2024

Dec 03, 2024

Lisata Therapeutics inks major deal with Kuva Labs By Investing.com - Investing.com Canada

Dec 03, 2024

Dec 03, 2024

Lisata Therapeutics Enters Global Collaboration with Kuva Labs to Advance Tumor Imaging Technology - Proactive Investors UK

Dec 03, 2024

Dec 03, 2024

Lisata Therapeutics, Inc. and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging - Marketscreener.com

Dec 03, 2024